CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 222 participants.
Also called NCT03998163
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 222 participants
- Sponsor
- Registry
-
NCT03998163
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Hungary, Poland
- Registry status
- Completed
Technical summary
Registry record NCT03998163. Allocation not applicable; no masking; primary purpose treatment. Start 2019-05-06 (actual); primary completion 2020-02-26 (actual). Results posted on 2021-10-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
- Condition
- Uremic Pruritus
- Intervention (Drug)
- CR845 0.5 mcg/kg
- Lead sponsor
- Cara Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03998163- Content hash
ef9203b734333cb0eed374095e166498fc87dfe46abebf7dc5596bd40590a2b1